Takeda has announced FDA approval for its oral drug, FRUZAQLA™ (fruquintinib), designed to treat adults with metastatic colorectal cancer who have previously received chemotherapy, anti-VEGF, and applicable anti-EGFR therapies.

Several selective CDK7 inhibitors, which have entered clinical trials, have demonstrated effective anti-cancer results in numerous pre-clinical models.

The EU has sanctioned VANFLYTA®, the initial FLT3 inhibitor tailored for recently identified patients with FLT3-ITD positive AML.

The ESMO Congress presented a summary of the RATIONALE-315 phase III trial: Neoadjuvant tislelizumab plus platinum-based chemotherapy showed a pathological response in operable stage II-IIIA NSCLC, prompting detailed trial result discussions.

This article summarized the latest R&D progress of Tirbanibulin, the Mechanism of Action for Tirbanibulin, and the drug target R&D trends for Tirbanibulin.

CETP inhibitors are drugs designed to increase HDL-C levels which can improve cardiovascular health.

Orum Therapeutics has announced a final agreement with Bristol Myers Squibb for the acquisition of its ORM-6151 program.

On 23 Oct 2023, liquid biopsies (LBx) and tissue biopsies (TBx) for identifying MET exon 14 (METex14) skipping in advanced NSCLC: Analyses from the phase II VISION study of tepotinib was reported at the ESMO Congress.

This article summarized the latest R&D progress of Tolcapone, the Mechanism of Action for Tolcapone, and the drug target R&D trends for Tolcapone.

In biology, a neoantigen refers to a novel antigen that arises from a mutation in the DNA of a normal cell.

BioRay introduces the initiation of its Phase I clinical trial with the first patient for BRY812, a new LIV-1 focused antibody drug conjugate.

CDK4 inhibitors can inhibit the formation of complexes between CDK4 and cyclin D, block ATP binding, thereby severing upstream growth signals, and prevent the transition from G1 to S phase.